Logo image of TARA

PROTARA THERAPEUTIC INC (TARA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TARA - US74365U1079 - Common Stock

7.26 USD
+0.82 (+12.73%)
Last: 11/21/2025, 8:01:51 PM
7.15 USD
-0.11 (-1.52%)
After Hours: 11/21/2025, 8:01:51 PM
Fundamental Rating

3

TARA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 535 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TARA as it has an excellent financial health rating, but there are worries on the profitability. TARA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TARA had negative earnings in the past year.
TARA had a negative operating cash flow in the past year.
In the past 5 years TARA always reported negative net income.
TARA had a negative operating cash flow in each of the past 5 years.
TARA Yearly Net Income VS EBIT VS OCF VS FCFTARA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a decent Return On Assets value of -36.58%, TARA is doing good in the industry, outperforming 62.43% of the companies in the same industry.
Looking at the Return On Equity, with a value of -39.99%, TARA is in the better half of the industry, outperforming 71.78% of the companies in the same industry.
Industry RankSector Rank
ROA -36.58%
ROE -39.99%
ROIC N/A
ROA(3y)-44.56%
ROA(5y)-35.55%
ROE(3y)-50.02%
ROE(5y)-39.26%
ROIC(3y)N/A
ROIC(5y)N/A
TARA Yearly ROA, ROE, ROICTARA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

TARA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TARA Yearly Profit, Operating, Gross MarginsTARA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

TARA has more shares outstanding than it did 1 year ago.
TARA has more shares outstanding than it did 5 years ago.
TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TARA Yearly Shares OutstandingTARA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TARA Yearly Total Debt VS Total AssetsTARA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 10.54 indicates that TARA is not in any danger for bankruptcy at the moment.
TARA's Altman-Z score of 10.54 is amongst the best of the industry. TARA outperforms 83.36% of its industry peers.
TARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.54
ROIC/WACCN/A
WACCN/A
TARA Yearly LT Debt VS Equity VS FCFTARA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 13.69 indicates that TARA has no problem at all paying its short term obligations.
The Current ratio of TARA (13.69) is better than 89.91% of its industry peers.
A Quick Ratio of 13.69 indicates that TARA has no problem at all paying its short term obligations.
TARA has a better Quick ratio (13.69) than 90.09% of its industry peers.
Industry RankSector Rank
Current Ratio 13.69
Quick Ratio 13.69
TARA Yearly Current Assets VS Current LiabilitesTARA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.94% over the past year.
EPS 1Y (TTM)48.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.67% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y41.68%
EPS Next 2Y13.76%
EPS Next 3Y7.67%
EPS Next 5Y14.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TARA Yearly Revenue VS EstimatesTARA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2027 2028 2029 2030 2031 2032 100M 200M 300M
TARA Yearly EPS VS EstimatesTARA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TARA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TARA Price Earnings VS Forward Price EarningsTARA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TARA Per share dataTARA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.76%
EPS Next 3Y7.67%

More info and screens

0

5. Dividend

5.1 Amount

TARA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTARA THERAPEUTIC INC

NASDAQ:TARA (11/21/2025, 8:01:51 PM)

After market: 7.15 -0.11 (-1.52%)

7.26

+0.82 (+12.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-03 2026-03-03/amc
Inst Owners77.18%
Inst Owner Change-14.09%
Ins Owners2.82%
Ins Owner Change1.46%
Market Cap280.16M
Revenue(TTM)N/A
Net Income(TTM)-52.90M
Analysts83.33
Price Target25.5 (251.24%)
Short Float %7.54%
Short Ratio5.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.06%
Min EPS beat(2)15.27%
Max EPS beat(2)20.85%
EPS beat(4)4
Avg EPS beat(4)22.05%
Min EPS beat(4)14.97%
Max EPS beat(4)37.1%
EPS beat(8)7
Avg EPS beat(8)17.41%
EPS beat(12)9
Avg EPS beat(12)4.01%
EPS beat(16)12
Avg EPS beat(16)4.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.17%
PT rev (3m)12.78%
EPS NQ rev (1m)15.05%
EPS NQ rev (3m)8.38%
EPS NY rev (1m)0%
EPS NY rev (3m)1.57%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB 2.12
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-1.7
Fwd EYN/A
FCF(TTM)-1.25
FCFYN/A
OCF(TTM)-1.25
OCFYN/A
SpS0
BVpS3.43
TBVpS3.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -36.58%
ROE -39.99%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.56%
ROA(5y)-35.55%
ROE(3y)-50.02%
ROE(5y)-39.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -18.3%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.69
Quick Ratio 13.69
Altman-Z 10.54
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)26.72%
Cap/Depr(5y)292.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38%
EPS Next Y41.68%
EPS Next 2Y13.76%
EPS Next 3Y7.67%
EPS Next 5Y14.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.29%
OCF growth 3YN/A
OCF growth 5YN/A

PROTARA THERAPEUTIC INC / TARA FAQ

What is the fundamental rating for TARA stock?

ChartMill assigns a fundamental rating of 3 / 10 to TARA.


Can you provide the valuation status for PROTARA THERAPEUTIC INC?

ChartMill assigns a valuation rating of 0 / 10 to PROTARA THERAPEUTIC INC (TARA). This can be considered as Overvalued.


What is the profitability of TARA stock?

PROTARA THERAPEUTIC INC (TARA) has a profitability rating of 1 / 10.


What is the financial health of PROTARA THERAPEUTIC INC (TARA) stock?

The financial health rating of PROTARA THERAPEUTIC INC (TARA) is 8 / 10.


What is the earnings growth outlook for PROTARA THERAPEUTIC INC?

The Earnings per Share (EPS) of PROTARA THERAPEUTIC INC (TARA) is expected to grow by 41.68% in the next year.